Cargando…

Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes

This study assessed the endocrine pancreatic responses to liraglutide (0.9 mg once a day) during normal living conditions in Japanese patients with type 2 diabetes. The study included 14 hospitalized patients with type 2 diabetes. Meal tests were performed after improvement of glycemic control achie...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Shinobu, Yamazaki, Masahiro, Kadono, Mayuko, Iwase, Hiroya, Kobayashi, Kanae, Okada, Hiroshi, Fukui, Michiaki, Hasegawa, Goji, Nakamura, Naoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: the Society for Free Radical Research Japan 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705157/
https://www.ncbi.nlm.nih.gov/pubmed/23874074
http://dx.doi.org/10.3164/jcbn.13-14
_version_ 1782476394409754624
author Matsumoto, Shinobu
Yamazaki, Masahiro
Kadono, Mayuko
Iwase, Hiroya
Kobayashi, Kanae
Okada, Hiroshi
Fukui, Michiaki
Hasegawa, Goji
Nakamura, Naoto
author_facet Matsumoto, Shinobu
Yamazaki, Masahiro
Kadono, Mayuko
Iwase, Hiroya
Kobayashi, Kanae
Okada, Hiroshi
Fukui, Michiaki
Hasegawa, Goji
Nakamura, Naoto
author_sort Matsumoto, Shinobu
collection PubMed
description This study assessed the endocrine pancreatic responses to liraglutide (0.9 mg once a day) during normal living conditions in Japanese patients with type 2 diabetes. The study included 14 hospitalized patients with type 2 diabetes. Meal tests were performed after improvement of glycemic control achieved by two weeks of multiple insulin injection therapy and after approximately two weeks of liraglutide treatment. Continuous glucose monitoring was performed to compare daily variation in glycemic control between multiple insulin injection therapy and liraglutide treatment. Liraglutide reduced plasma glucose levels after the test meals (60–180 min; p<0.05), as a result of significant increases in insulin secretion (0–180 min; p<0.05) and decreases in the incremental ratio of plasma glucagon (15–60 min; p<0.05). Continuous glucose monitoring showed that liraglutide treatment was also associated with a decrease in glucose variability. We also demonstrated that optimal glycemic control seen as a reduction in 24-h mean glucose levels and variability was obtained only with liraglutide monotherapy. In conclusion, liraglutide treatment increases insulin secretion and suppresses glucagon secretion in Japanese patients with type 2 diabetes under normal living conditions. The main therapeutic advantages of liraglutide are its use as monotherapy and its ability to decrease glucose variability.
format Online
Article
Text
id pubmed-3705157
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher the Society for Free Radical Research Japan
record_format MEDLINE/PubMed
spelling pubmed-37051572013-07-19 Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes Matsumoto, Shinobu Yamazaki, Masahiro Kadono, Mayuko Iwase, Hiroya Kobayashi, Kanae Okada, Hiroshi Fukui, Michiaki Hasegawa, Goji Nakamura, Naoto J Clin Biochem Nutr Original Article This study assessed the endocrine pancreatic responses to liraglutide (0.9 mg once a day) during normal living conditions in Japanese patients with type 2 diabetes. The study included 14 hospitalized patients with type 2 diabetes. Meal tests were performed after improvement of glycemic control achieved by two weeks of multiple insulin injection therapy and after approximately two weeks of liraglutide treatment. Continuous glucose monitoring was performed to compare daily variation in glycemic control between multiple insulin injection therapy and liraglutide treatment. Liraglutide reduced plasma glucose levels after the test meals (60–180 min; p<0.05), as a result of significant increases in insulin secretion (0–180 min; p<0.05) and decreases in the incremental ratio of plasma glucagon (15–60 min; p<0.05). Continuous glucose monitoring showed that liraglutide treatment was also associated with a decrease in glucose variability. We also demonstrated that optimal glycemic control seen as a reduction in 24-h mean glucose levels and variability was obtained only with liraglutide monotherapy. In conclusion, liraglutide treatment increases insulin secretion and suppresses glucagon secretion in Japanese patients with type 2 diabetes under normal living conditions. The main therapeutic advantages of liraglutide are its use as monotherapy and its ability to decrease glucose variability. the Society for Free Radical Research Japan 2013-07 2013-06-01 /pmc/articles/PMC3705157/ /pubmed/23874074 http://dx.doi.org/10.3164/jcbn.13-14 Text en Copyright © 2013 JCBN This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Matsumoto, Shinobu
Yamazaki, Masahiro
Kadono, Mayuko
Iwase, Hiroya
Kobayashi, Kanae
Okada, Hiroshi
Fukui, Michiaki
Hasegawa, Goji
Nakamura, Naoto
Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes
title Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes
title_full Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes
title_fullStr Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes
title_full_unstemmed Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes
title_short Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes
title_sort effects of liraglutide on postprandial insulin and glucagon responses in japanese patients with type 2 diabetes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705157/
https://www.ncbi.nlm.nih.gov/pubmed/23874074
http://dx.doi.org/10.3164/jcbn.13-14
work_keys_str_mv AT matsumotoshinobu effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes
AT yamazakimasahiro effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes
AT kadonomayuko effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes
AT iwasehiroya effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes
AT kobayashikanae effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes
AT okadahiroshi effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes
AT fukuimichiaki effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes
AT hasegawagoji effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes
AT nakamuranaoto effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes